You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Earnings call GSK delivered a strong Q1 2026 with sales up 5% YoY to over GBP 7.6 billion, driven by Specialty Medicines (+14%) and record Shingrix sales (+20%). Core operating profit rose 10%, EPS ...

GSK (GSK) reported better-than-expected financials for Q1 2026 on Wednesday as sales from its HIV and cancer medicines offset a sales decline for its general medicines, including its respiratory ...

In GSK’s first quarter under Luke Miels as CEO, the company’s flagship shingles vaccine, Shingrix, set a new quarterly sales record, while its closely watched asthma launch, Exdensur, showed “early ...

Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday AstraZeneca CEO Pascal Soriot said that if ...

The blue chip pharma saw sales rise 2%, or by 5% on a constant currency basis, to £7.6bn, while core earnings per share came in at 46.5p per share, up 9% and ahead of consensus for 43.3p. Speciality ...

GSK GSK1.32%increase; green up pointing triangle reported higher earnings on increased specialty medicine sales and said it expects to pay a total dividend this year of 70 pence a share. The FTSE ...

When it comes to GSK’s new dealmaking strategy of trying to outdo established blockbusters, CEO Luke Miels has told Fierce that oncology may offer the most tempting targets. Miels—who served as GSK’s ...

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an antibody-drug conjugate (ADC). That deal, signed back in 2022, centered on XMT ...

LONDON, April 29 (Reuters) - Strong first-quarter results under new GSK (GSK.L), opens new tab CEO Luke Miels on Wednesday failed to impress investors, who raised concerns ‌that the British ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GSK delivered Q1 core earnings of 46.5p per share, surpassing the 43.5p consensus forecast Approximately 50% of the profit outperformance stemmed from legal settlement adjustments rather than ...